CureVac Downsizes COVID-19 Vaccine Manufacturing

CureVac is cancelling production deals with two European contract manufacturers tasked with producing the drug substance for the German company’s messenger RNA (mRNA) COVID-19 vaccine, CVnCoV, which is currently being evaluated by the European Medicines Agency. 

CureVac said contracts with the two companies, Wacker and the Celonic Group, were being cancelled because of the increased demand for already approved products, including the Pfizer/BioNTech and Moderna mRNA-based vaccines.

However, CureVac said that its vaccine production deals with Novartis and Rentschler Biopharma will remain in place.